Ain Holdings Inc. · TSE:9627
Ain — Ain Pharmaciez — Q2 FY4/13 Earnings Presentation
10 slides from Ain's earnings presentation, December 2012
Slide 1: IR Presentation
IR PRESENTATION December 2012
Slide 2: Results Overview
Results Overview © 2012 AIN PHARMACIEZ Inc. All Rights Reserved. 1
Slide 3: Consolidated P/L
Consolidated P/L Net sales increased 9.1% year on year to ¥75,090 million, operating income declined 12.0% to ¥4,209 million, ordinary income fell 8.6% to ¥4,454 million, and net income declined 9.6% to ¥2,137 million. FY4/12 2Q FY4/13 2Q FY4/13 2Q YoY Vs plan YoY change (¥ million) results plan res
Slide 4: Dispensing Pharmacy Business (Consolidated)
Dispensing Pharmacy Business（Consolidated） The dispensing pharmacy business reported sales growth of 8.5% year on year to ¥66,622 million. However, segment income declined 1.3% to ¥5,682 million due to the impact of startup costs for medical malls. FY4/12 2Q FY4/13 2Q FY4/13 2Q YoY Vs plan YoY chang
Slide 5: Drug and Cosmetic Store Business (Consolidated)
Drug and Cosmetic Store Business(Consolidated) The drug and cosmetic store business reported an increase in sales of 12.3% year on year to ¥8,208 million. However, segment income declined 50.0% to ¥26 million. FY4/12 2Q FY4/13 2Q FY4/13 2Q YoY Vs plan YoY change (¥ million) results plan results chan
Slide 6: Consolidated B/S
Consolidated B/S The balance of interest-bearing debt increased by ¥1,336 million to ¥14,051 million. The balance of total assets at the end of the second quarter increased by ¥6,603 million from the end of the previous fiscal year to ¥92,511 million. Total net assets increased by ¥1,352 million to
Slide 7: Assets
Assets The balance of total assets at the end of the second quarter increased by ¥6,603 million from the end of the previous fiscal year to ¥92,511 million. End-FY4/12 2Q End-FY4/12 End-FY4/13 2Q Change (¥ million) Cash on hand and in banks 18,355 15,935 14,853 (1,082) Notes and accounts receivable
Slide 8: Liabilities and Net Assets
Liabilities and Net Assets The balance of total liabilities rose ¥5,251 million to ¥57,413 million, mainly reflecting an increase in accounts payable. End-FY4/12 2Q End-FY4/12 End-FY4/13 2Q Change (¥ million) Accounts payable 21,834 22,524 25,255 2,731 Short-term debt 5,965 6,397 7,823 1,426 Total c
Slide 9: Consolidated P/L (Progress rate)
Consolidated P/L（Progress rate） The FY4/13 2Q results make progress for the FY4/13 full-year plan smoothly. FY4/12 FY4/13 YoY YoY change FY4/13 2Q Vs full-year (¥ million) results plan change (%) results plan (%) Net sales 142,790 157,500 14,710 110.3 75,090 47.7 Gross profit 23,093 25,890 2,797 112
Slide 10: Ain Pharmaciez Inc. Corporate Planning Division Contact
Inquiries related to this presentation should be addressed to AIN PHARMACIEZ INC. Corporate Planning Division TEL(81)11-783-5681 FAX(81)11-783-0224 E-MAIL: [email protected] http://www.ainj.co.jp/ This document may not be reproduced or distributed to any third party without prior approval of AIN PHA